Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial

The Lancet

Volumn 373, Issue 9665, 2009, Pages 732-738

  Goodman, Andrew D ^a   Brown, Theodore R ^b   Krupp, Lauren B ^c   Schapiro, Randall T ^d   Schwid, Steven R ^a   Cohen, Ron ^e   Marinucci, Lawrence N ^e   Blight, Andrew R ^e  

^a UNIVERSITY OF ROCHESTER   (United States)

^b Evergreen Hospital Medical Center   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d Minneapolis Clinic of Neurology   (United States)

^e ACORDA THERAPEUTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; PLACEBO;

ADULT; AGED; ARTICLE; ASTHENIA; BACKACHE; BALANCE DISORDER; CLINICAL TRIAL; COMPUTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FALL RISK; FATIGUE; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAUSEA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; SUSTAINED DRUG RELEASE; TABLET; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WALKING; WALKING DIFFICULTY;

EID: 60649090430     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60442-6     Document Type: Article

References (30)

1. Lechat P., Thesleff S., and Bowman W.C. Aminopyridines and similarly acting drugs, effects on nerves, muscles and synapses (1982), Pergamon Press, Oxford
2. Judge S.I., and Bever Jr. C.T. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 111 (2006) 224-259
3. Stefoski D., Davis F.A., Fitzsimmons W.E., et al. 4-aminopyridine in multiple sclerosis: prolonged administration. Neurology 41 (1991) 1344-1348
4. van Diemen H.A., Polman C.H., van Dongen T.M., et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 32 (1992) 123-130
5. Bever Jr. C.T., Young D., Anderson P.A., et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 44 (1994) 1054-1059
6. Schwid S.R., Petrie M.D., McDermott M.P., et al. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 48 (1997) 817-821
7. Solari A., Uitdehaag B., Giuliani G., Pucci E., and Taus C. Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst Rev 2 (2002) CD001330.
8. Goodman A.D., Cohen J.A., Cross A., et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Multiple Sclerosis 13 (2007) 357-368
9. Goodman A.D., Brown T.R., Cohen J.A., et al. Dose-comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 71 (2008) 1134-1141
10. Hayes K.C., Katz M.A., Devane J.G., et al. Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. J Clin Pharmacol 43 (2003) 379-385
11. Hayes K.C., Potter P.J., Hsieh J.T., et al. Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. Arch Phys Med Rehabil 85 (2004) 29-34
12. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
13. Cohen R.A., Kessler H.R., and Fischer M. The Extended Disability Status Scale (EDSS) as a predictor of impairments of functional activities of daily living in multiple sclerosis. J Neurol Sci 115 (1993) 132-135
14. Hobart J.C., Riazi A., Lamping D.L., Fitzpatrick R., and Thompson A.J. Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology 60 (2003) 31-36
15. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50 (2001) 121-127
16. Fischer J.S., Jak A.J., Kniker J.E., et al. Multiple Sclerosis Functional Composite (MSFC): administration and scoring manual (2001), National Multiple Sclerosis Society, New York
17. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 192 (1964) 540-542
18. Medical Research Council (MRC). Aids to the investigation of peripheral nerve injuries (1976), HM Stationery Office, London
19. Albrect H., Wotzel C., Erasmus L.P., et al. Day-to-day variability of maximum walking distance in MS patients can mislead to relevant changes in the Expanded Disability Status Scale (EDSS): average walking speed is a more constant parameter. Multiple Sclerosis 7 (2001) 105-109
20. Schwid S.R., Goodman A.D., Mattson D.H., et al. The measurement of ambulatory impairment in multiple sclerosis. Neurology 49 (1997) 1419-1424
21. Cohen J.A., Fischer J.S., Bolibrush D.M., et al. Intrarater and interrater reliability of the MS functional composite outcome measure. Neurology 54 (2000) 802-806
22. Cohen J.A., Cutter G.R., Fischer J.S., et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 58 (2001) 961-967
23. Ozakbas S., Cagiran I., Ormeci B., and Idiman E. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis. J Neurol Sci 218 (2004) 3-7
24. Kaufman M., Moyer D., and Norton J. The significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite. Multiple Sclerosis 6 (2000) 286-290
25. Schwid S.R., Goodman A.D., McDermott M.P., Bever C.F., and Cook S.D. Quantitative functional measures in MS: what is a reliable change?. Neurology 58 (2002) 1294-1296
26. Kragt J.J., van der Linden F., Nielsen J.M., Uitdehaag B.M.J., and Polman C.H. Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Multiple Sclerosis 12 (2006) 594-598
27. Dobkin B. Short-distance walking speed and timed walking distance: redundant measures for clinical trials?. Neurology 66 (2006) 584-586
28. Creange A., Serre I., Audrey D., et al. Walking capacities in multiple sclerosis measured by global positioning system odometer. Multiple Sclerosis 13 (2007) 220-223
29. Fahey M.C., Corben L.A., Collins V., Churchyard A.J., and Delatycki M.B. The 25-foot walk velocity accurately measures real world ambulation in Friedreich ataxia. Neurology 68 (2007) 705-706
30. Koch M., Uyttenboogaart M., Polman S., and De Keyser J. Seizures in multiple sclerosis. Epilepsia 49 (2008) 948-953